|
|
|
|
|
Info: Your browser does not accept cookies. If you want to put products into your cart and purchase them you need to enable cookies.
Browse
Cancer Highlights is a publication series covering key topics in the field of oncology. It focuses on R&D and business development. Cancer Highlights has 14 publications in total, covering three main topics updated over an 18 months cycle.
Each publication is written by BioSeeker's oncology professionals who have years of experience analyzing cancer R&D and business development. |  | BioSeeker's knowledge base in oncology includes more than 1,000 cancer R&D companies and close to 3,000 drugs, from drug discovery to marketed.
Cancer Highlights is designed by BioSeeker to assist and enhance our readers' business insights and intelligence in oncology. These reports will assist to: - improve competitor analysis
- outline R&D alignments
- identify and follow trends and future insights
- identify key breakthroughs important for your company
- track cutting edge companies, therapies and new technologies
- save significant time in identifying your partners & competitors
|
Currently Druggable in Prostate Cancer
This report is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of prostate cancer drugs.
Decoding Big Pharmas R&D Strategy in Oncology
This report, Decoding Big Pharma’s R&D Strategy in Oncology, is based on five major pharmaceutical companies in the oncology arena: Bristol-Myers Squibb, GlaxoSmithKline, Hoffmann-La Roche, and Sanofi-Aventis.
Cancer Vaccines: Aim and Shoot
This report aims to analyze the current and future potential of cancer vaccines by examining key fundamentals across the entire pipeline of cancer vaccine drug candidates.
Global Cancer Focus Company Directory
Global Cancer Focus Company Directory pulls out virtually all cancer drug developing companies in the world. After several acquisitions and mergers in the market place, BioSeeker offers you the tool to get an updated look on the competitive landscape
Currently Druggable in Melanoma
This report is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of melanoma drugs.
Competitive Insights to Anti-Angiogenic Drug R&D in Oncology
This report is written for you to identify your competition and understand which targeting strategies are at work within anti-angiogenic drug development in oncology. It allows you to pin-point which competitors drugs’ clinical out-come may have
Cancer Antibodies: Competitive Positioning for Success
This report is written for you to identify your competition and understand which targeting strategies are at work within antibody drug development. It allows you to pin-point which competitors drugs’ clinical out-come may have bearing on your ow
Antibody Drug Target Atlas in Oncology
First of its kind, "Antibody Drug Target Atlas in Oncology" provides a comprehensive analysis of the commercialization of antibody drug targets in oncology
The Drug Target Atlas of Apoptopic Drugs in Oncology
First in place, BioSeeker has surveyed apoptopic drugs in oncology and identified 119 drug targets, belonging to 114 drugs. This report, The Drug Target Atlas of Apoptopic Drugs in Oncology, is an open landscape of resources to build, fuel, and drive
Currently Druggable in Breast Cancer
This report aims to analyze the current and future potential of breast cancer pipeline by examining key fundamentals across the entire pipeline of drug candidates. BioSeeker has identified three fundamental dimensions to outline the competitive landsc
Melanoma - Targeted Therapeutics
This in-depth analysis of the progress of melanoma R&D and current treatment strategies is one of the most extensive reports available in this field.
Deployment of Antibody Technologies in Oncology
The discovery of new cancer therapeutics has seen a significant shift towards biologicals as an alternative to small molecule drugs. Targeted biologics utilizing monoclonal antibody-based technologies have rapidly developed into one of the major marke
Apoptosis: Promise or deception?
In this publication, BioSeeker Group analyzes the latest progress made for 25 drug candidates targeting the cell death pathway, apoptosis. Additionally, more early stage candidates are also under investigation, which brings the total number of compan
Cancer Vaccines Fantasy or Future?
In this newly updated progress analysis, BioSeeker not only provide a solid background and information structure, we also bring the latest within cancer vaccine achievements.
Large Pharma:2004 a year of Progress
BioSeeker Group analyzes the progress made by the large pharmaceutical companies top oncology drug candidates whom has reached Phase III clinical evaluation.
Current and Future Therapies for Colorectal Cancer
Colorectal cancer (CRC) is the second most common cause of cancer death in much of the developed world. Cancer-related mortality is slowly decreasing as a result of better detection and significant advances in the treatment of advanced colorectal canc
The Commercial Success of Cancer Therapeutic Antibodies
The blockbuster drugs Rituxan, Avastin, and Erbitux have change the way the industry looks upon antibody treatment of cancer in the same way that Taxol changed the way pharmaceutical companies look at the possibilities in the field of cancer therapeut
Leukemia - A Therapeutic & Competitive Insight
In the report "Leukemia - A Therapeutic & Competitive Insight" BioSeeker does not only describe and analyze the latest years of progress in four different market segments; CLL, CML ALL and AML, but also provide an insight and framework to un
New Concepts in Cancer Therapeutics
There are, at present, ten times more anticancer drugs being tested in clinical trials than there were 20 years ago. Many of the new classes of agents....
| | |
